BRIEF-Prometic Life Sciences confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

Tue Mar 22, 2016 6:41am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

March 22 (Reuters) - Prometic Life Sciences Inc

* Confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

* Statistically significant decrease in novel biomarkers associated with a high risk of cardiovascular events

* Results further support PBI-4050's pharmacological activity and clinical benefits in patients

* PBI-4050 has demonstrated a "very good" safety and tolerability profile, with no drug-related serious adverse events Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)